34 results
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
, social and governance, or ESG, expectations, physical and transition risks associated with climate change, and emerging ESG regulation and policy … and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management
F-1
EVAX
Evaxion Biotech A/S
12 Jan 24
Registration statement (foreign)
5:17pm
responses to such change.
Increasing stakeholder environmental, social and governance, or ESG, expectations, physical and transition risks associated … effective disclosure and financial controls and corporate governance practices. Our management and other personnel have devoted and will continue to devote
424B4
EVAX
Evaxion Biotech A/S
13 Sep 23
Prospectus supplement with pricing info
4:45pm
Denmark. Public limited liability companies in Denmark are usually subject to a two-tier governance structure with the board of directors having
POS AM
EVAX
Evaxion Biotech A/S
25 Aug 23
Prospectus update (post-effective amendment)
5:00pm
governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management of the company
6-K
EX-1.1
whdyvxf7zboulr3g7qv
4 Oct 22
Current report (foreign)
8:56am
424B5
qtm29yosu0
4 Oct 22
Prospectus supplement for primary offering
8:52am
424B4
yl70k phc
30 Aug 22
Prospectus supplement with pricing info
4:52pm
F-1/A
2pelft21t1q8zs6wb
22 Aug 22
Registration statement (foreign) (amended)
4:40pm
F-1
8eebhej
7 Jul 22
Registration statement (foreign)
4:45pm
F-3
tirakpo
20 May 22
Shelf registration (foreign)
5:22pm
424B4
gz6avp
5 Nov 21
Prospectus supplement with pricing info
4:47pm
6-K
EX-1.1
3am1 leyql
5 Nov 21
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
8:30am
F-1/A
p6xpdxu0ymvpwqbv
3 Nov 21
Registration statement (foreign) (amended)
7:50am
F-1
ebwqpta4wyht
26 Oct 21
Registration statement (foreign)
7:02am
F-1
EX-1.1
y65za33
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.2
eqfs 2w11
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
DRS
jdupvnw9k2 adzdrt
25 Jun 21
Draft registration statement
12:00am